LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Lista de Ações・Puma Biotechnology Inc

Puma Biotechnology Inc

Fechado

SetorSaúde

6.99 -0.14

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

6.98

Máximo

7.03

Indicadores-chave
By Trading Economics
Rendimento	-16M -3.8M
Vendas	-31M 45M
P/E Médio do Setor	14.833 49.888
EPS	-0.04
Margem de lucro	-8.375
Funcionários	179
EBITDA	-28M -1.3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-28.88% downside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-21M 362M
Abertura anterior	7.13
Fecho anterior	6.99

Sentimento de Notícias

By Acuity

50%

155 / 344 Ranking em Healthcare

Puma Biotechnology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2026, 19:20 UTC

Grandes Movimentos do Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 de jun. de 2026, 21:27 UTC

Ganhos

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 20:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 de jun. de 2026, 20:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 de jun. de 2026, 19:10 UTC

Conversa de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 de jun. de 2026, 19:03 UTC

Conversa de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 de jun. de 2026, 18:59 UTC

Conversa de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 de jun. de 2026, 18:47 UTC

Conversa de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 de jun. de 2026, 18:34 UTC

Conversa de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 de jun. de 2026, 18:33 UTC

Aquisições, Fusões, Aquisições de Empresas

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 de jun. de 2026, 17:50 UTC

Ganhos

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 de jun. de 2026, 17:27 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 de jun. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

5 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 15:26 UTC

Conversa de Mercado

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 de jun. de 2026, 15:25 UTC

Ganhos

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 de jun. de 2026, 15:16 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 15:16 UTC

Conversa de Mercado

Zcash Tumbles After Exploit Found -- Market Talk

5 de jun. de 2026, 15:09 UTC

Conversa de Mercado

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 de jun. de 2026, 15:07 UTC

Conversa de Mercado

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 de jun. de 2026, 15:05 UTC

Conversa de Mercado

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparação entre Pares

Variação de preço

Puma Biotechnology Inc Previsão

Preço-alvo

By TipRanks

-28.88% parte inferior

Previsão para 12 meses

Média 5 USD -28.88%

Máximo 5 USD

Mínimo 5 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Puma Biotechnology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Puma Biotechnology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

155 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.